Meeting
2015 ASCO Annual Meeting
Epidemiology, treatment (tx) patterns and outcomes in Asian soft tissue sarcoma (STS) patients: Results from the Soft Tissue Sarcoma in the Asia Pacific Region (STAR) study.
Authors
Richard Hong Hui Quek
National Cancer Centre, Division of Medical Oncology, Singapore, Singapore
Richard Hong Hui Quek , Mohamad Farid , Edward Wang , Apichat Asavamongkolkul , Alex Leung , Nugroho Prayogo , Thipachart Punyaratabandhu , Ee-Min Yeoh , Sumitra Shantakumar , Stephanie Manson , Roger K.C. Ngan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Citation
J Clin Oncol 33, 2015 (suppl; abstr 10549)
DOI
10.1200/jco.2015.33.15_suppl.10549
Abstract #
10549
Poster Bd #
193
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib (2ND-STEP, JCOG1802).
First Author: Makoto Endo
Poster
2015 ASCO Annual Meeting
Phase 2 study of gemcitabine, docetaxel, and doxorubicin in patients with advanced, unresectable, and/or metastatic sarcoma who have failed prior therapies.
First Author: Andrew Eugene Hendifar
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.
First Author: Sarmad Sadeghi
Poster
2019 ASCO Annual Meeting
A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib (REG) in patients (pts) with nonadipocytic soft tissue sarcoma (STS) previously treated with pazopanib (PAZ).
First Author: Nicolas Penel